BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20250101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260428
DTEND;VALUE=DATE:20260501
DTSTAMP:20260514T224212
CREATED:20260107T093116Z
LAST-MODIFIED:20260107T093116Z
UID:42669-1777334400-1777593599@www.pharmajournalist.com
SUMMARY:5th ADC Analytical Development Summit
DESCRIPTION:The 5th ADC Analytical Development Summit is the industry’s only dedicated technical forum focused exclusively on solving the analytical challenges unique to antibody–drug conjugate (ADC) development. Designed for analytical\, bioanalytical\, and CMC leaders\, the summit brings together senior experts from across pharma and biotech to advance analytical rigor\, deepen product understanding\, and enable regulatory-ready ADC submissions as modalities grow increasingly complex. \nWhy Attend \n\nAcross three content-packed days\, attendees will gain practical insights to:\nOptimize physicochemical\, potency\, and impurity analytical methods\nDecode ADC heterogeneity and move beyond average DAR measurements\nDevelop biologically relevant bioassays for next-generation ADCs\nNavigate evolving regulatory expectations and strengthen CMC strategies\nStreamline analytical method transfer to QC and CDMOs\n\nWith actionable case studies and real-world lessons\, you’ll stay ahead as bispecifics\, dual payloads\, and novel conjugate formats progress through development pipelines. \nProgram Highlights \n\n22+ expert speakers from leading biopharma and biotech companies\n3 in-depth workshops on advanced ADC analytical strategies\n4+ panel discussions addressing current technical challenges\n12+ hours of structured networking with 80+ senior analytical scientists\n\nFeatured Speakers Include \nFrancis Poulin (Takeda)\, Melvin Flores (Sutro Biopharma)\, John Valliere-Douglas (Pfizer)\, Adrienne Wildt (AbbVie)\, Susan Clardy (Pyxis Oncology)\, and Stacey Cummins-Bitz (Eli Lilly)\, alongside experts from AstraZeneca\, Merck\, BMS\, Johnson & Johnson\, and more. \nDownload the full Event Guide to explore the complete agenda\, workshops\, and speaker faculty: https://ter.li/opm2ur
URL:http://www.pharmajournalist.com/event/5th-adc-analytical-development-summit/
LOCATION:Hotel Commonwealth\, 500 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260428
DTEND;VALUE=DATE:20260501
DTSTAMP:20260514T224212
CREATED:20260122T133529Z
LAST-MODIFIED:20260122T133529Z
UID:42745-1777334400-1777593599@www.pharmajournalist.com
SUMMARY:3rd Peptide-Based Therapeutics Summit 2026
DESCRIPTION:Peptide therapies are rapidly becoming a disruptive modality\, led by Merck’s oral PCSK9 inhibitor and Johnson & Johnson’s IL23R\, with the hope to develop best-in-class drugs with improved chemistry\, formulation and clinical efficacy. \nTo shine a light on the progress of this field\, the highly anticipated 3rd Peptide-Based Therapeutics Summit returns to Boston as the industry’s only dedicated platform to turbocharge the next generation of peptide discoveries through development and towards life-saving treatments. \nGathering industry leaders including Parabilis Medicines\, Circle Pharma\, Abbvie\, Merck\, Chugai Pharmaceuticals and many more\, this is your premium forum to explore: \n\nNovel computational tools\nOptimize analytical assays\nFormulating cell-specific delivery methods\nDMPK translatability towards clinical success of peptide therapies\n\nWith the likes of Alnylam\, Pfizer\, MIT\, Rapafusyn Pharma\, a stealth start-up and more already booked on to join\, be part of 100+ stakeholders from CEOs to Scientists in disciplines ranging from peptide drug discovery R&D\, medicinal chemistry\, pharmacology and formulation to accelerate this goldilocks modality from concept to commercialization. \nFor more information\, click here.
URL:http://www.pharmajournalist.com/event/3rd-peptide-based-therapeutics-summit-2026/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260428
DTEND;VALUE=DATE:20260501
DTSTAMP:20260514T224212
CREATED:20260227T124527Z
LAST-MODIFIED:20260227T124643Z
UID:43045-1777334400-1777593599@www.pharmajournalist.com
SUMMARY:5th GPCRs-Targeted Drug Discovery Summit
DESCRIPTION:The GPCR field is experiencing a renaissance\, driven by renewed investment\, clinical progress\, and next-generation technologies unlocking hundreds of previously untargeted receptors. Furthermore\, we’ve recently seen Takeda and Iambic Therapeutics’ $1.7bn partnership to advance AI-driven small molecule programs\, and Kainova Therapeutics securing $32m CAD to accelerate immuno-oncology and inflammation therapies\, momentum in the GPCR space continues to build. The race is on to validate new GPCRs\, understand dynamic activation mechanisms\, and develop assays that better predict therapeutic efficacy and guide smarter candidate selection. \nReturning as the only industry-led meeting dedicated to GPCR drug discovery\, the 5th GPCR-Targeted Drug Discovery Summit features a jam-packed agenda with: \n\n12+ companies unveiling never seen before data\n12+ C-Level speakers\n9+ presentations on non-small molecule GPCR-targeting drug discovery\n\nThis is the place to learn about the latest targets\, tools\, and therapeutic strategies. Join 80+ GPCR-focused leaders across biopharma to share insights\, build collaborations\, and accelerate next-generation therapeutics from discovery to clinic. \nTo know more visit: https://ter.li/etb3m3
URL:http://www.pharmajournalist.com/event/5th-gpcrs-targeted-drug-discovery-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR